Exchange Bulletin

BMO ARK Genomic Revolution Fund (ARKG) To Trade On Toronto Stock Exchange


November 15, 2022

Issuer: BMO ARK Genomic Revolution Fund (the "ETF")

SecuritySymbolIssued and Outstanding SecuritiesReserved SecuritiesIssue Price
ETF Series Units (the "Units") ARKG 100,000 None $15
Listing category: Non-Corporate
Trading currency: CDN$
Transaction: Initial public offering of Units (the "Offering")
Anticipated closing date: November 17, 2022
Listing date: November 16, 2022 (as at 5:01 pm) in anticipation of closing of the Offering.
Posted for trading date: November 17, 2022 (at the opening) subject to confirmation of closing of the Offering.
Other market(s): None
Designated market maker: BMO Nesbitt Burns Inc.
Investor relations: Kevin Gopaul
Head of Exchange Traded Funds, BMO Investments Inc.
416-359-7635
kevin.gopaul@bmo.com 
Incorporation: The ETF was established as a trust under the laws of the Province of Ontario pursuant to an amended and restated master declaration of trust dated November 1, 2022.
Manager and Trustee: BMO Investments Inc.
Fiscal year end: September 30
Nature of business: The ETF's objective is to provide long-term capital growth by investing primarily in equity securities of companies involved in disruptive genomic innovation from around the world.
Transfer agent and registrar: State Street Trust Company Canada at its principal offices in Toronto.
Distributions: Cash distributions on Units of the ETF, if any, are expected to be made on an annual basis.
Sponsorship: Not applicable
Offering document: Simplified Prospectus dated November 1, 2022, which is available at www.SEDAR.com. Capitalized terms not otherwise defined herein are as defined in the Prospectus.
Initial public offering: 100,000 Units will be issued at a subscription price of $15.00 per Unit. Units are being issued and sold on a continuous basis and there is no maximum number of Units that may be issued.
TSX contact: Selma Thaver,
Director,
TSX Listings